The global market for tuberculosis diagnostics expected to attain $4.7 billion by 2029, expanding at a CAGR of 5.8% over the forecast period, driven by increasing prevalence and incidence rates of tuberculosis, and technological advancements in development of rapid, accurate and easy to use tests.
- Other significant factors boosting the volume of TB diagnostic tests include tuberculosis awareness and control programs conducted by government and non-government organizations in various countries and the availability and high demand for technologically improved TB test kits in the market.
Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis. The bacteria usually attack the lungs but TB bacteria can attack any part of the body such as the kidney, spine and brain. Not everyone infected with TB bacteria becomes sick. As a result, two TB- related conditions exist: latent TB infection (LTBI) and TB disease.
- TB is the ninth leading cause of death worldwide and the leading cause from a single infectious agent, ranking above HIV/AIDS.
- An estimated 10.4 million people fell ill with TB in 2016: 90% were adults, 65% were male, 10% were people living with HIV (74% in Africa) and 56% were in five countries: India, Indonesia, China, the Philippines and Pakistan.
- About, 6.3 million new cases of TB are reported every year, equivalent to 61% of the estimated incidence of 10.4 million; the latest treatment outcome data show a global treatment success rate of 83%, similar to recent years.
- Most of the estimated number of incident cases have occurred in the South-East Asia region (45%), the African region (25%) and the Western Pacific region (17%); smaller proportions of cases occurred in the Eastern Mediterranean region (7%), the European region (3%) and the Americas (3%).
The global tuberculosis diagnostic testing market report provides market size ($million 2019 to 2029), market share, growth trends and forecast (CAGR%, 2023 to 2029).
The global tuberculosis diagnostics market segmented by test type (smear microscopy, culture-based tests, nucleic acid testing, Mantoux test / Tuberculin skin test, radiography/ chest X-ray, drug susceptibility testing, other serological tests, interferon gamma release assay, others), end user (hospitals, laboratories, others), and geography.
- Among the tuberculosis test types, the culture-based tests segment accounted for the major share of the total market, however it is anticipated to grow moderately throughout the forecast period.
- On the other hand, the serological tests segment is forecast grow at the fastest CAGR, followed by the nucleic acid-based testing segment during the next five year period.
- Other tests for tuberculosis testing include serological tests, IGRA (interferon-gamma release assays), ADA (adenosine deaminase) assay, and VOC (volatile organic compound) test, antibody-based, antigen-based, and other rapid TB tests.
- Culture-based methods remains the gold standard for TB diagnosis and phenotypic screening / phenotypic drug susceptibility tests (DST).
- However, the factors such as the time taken to produce the test results, and the need for considerable laboratory infrastructure and logistics limit their application only to the centralized facilities.
- Nucleic acid amplification technique (NAAT) is a rapid, highly sensitive, and specific method for the diagnosis of infectious diseases.
- Currently, NAAT is one of the largest groups of diagnostic technologies and products being offered by the manufacturers.
The global market for TB diagnostic testing research report is divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.
- In terms of geography, the Asia Pacific region accounted for the majority share of the total tuberculosis testing market, followed by the North America region.
- India and China have the highest tuberculosis affected patient population globally. Similarly, many countries in the APAC region recorded very high prevalence as well as incidence rates of TB disease.
- In the United States, there has been a decline in prevalence and incidence rates of TB over the last few decades. The Mantoux tests (TST) segment held the largest share of thew U.S. market, however DNA/RNA based tests segment forecast grow at a higher rate over the forecast period.
- Public awareness and availability of modern testing kits in developed markets has kept the TB growth rates to a minimum during the last few decades.
The global market for TB diagnostics report also provides detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major competitors operating in the global tuberculosis diagnostics market and included in this report are Abbott Laboratories, Inc., Akonni Biosystems, Inc., Becton, Dickinson and Company, bioMérieux SA, Cepheid, Inc., Epistem plc, Hain Lifescience GmbH, Hologic, Inc., Qiagen NV, Roche Holding AG (F. Hoffmann-La Roche AG), Sanofi SA, and Thermo Fisher Scientific, Inc.
- Smear Microscopy
- Culture Based Tests
- Nucleic Acid Testing
- Mantoux Test (Tuberculin Skin Test)
- Radiography (Chest X-Ray)
- Drug Susceptibility Testing (DST)
- Other Tests [Serological Tests, Interferon Gamma Release Assay (IGRA)]
- End User
- North America (U.S., Canada)
- Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
- Asia Pacific (Japan, China, India, Rest of APAC)
- Latin America (Brazil, Mexico, Rest of LA)
- Rest of the World
- Company Profiles
- Abbott Laboratories, Inc.
- Akonni Biosystems, Inc.
- Beckton, Dickinson and Company
- bioMerieux SA
- Cepheid, Inc.
- Epistem Holdings plc
- Hain Lifescience GmbH
- Hologic, Inc.
- Qiagen N.V.
- Roche Holding AG (F. Hoffmann-La Roche AG)
- Sanofi S.A.
- Thermo Fisher Scientific, Inc.
To request Table of Contents and Sample Pages of this report visit: